The research, led by Yao Peng and Yong Tan of Nanjing University of Chinese Medicine together with colleagues, set out to map what actually happens inside ovarian tissue after repeated exposure to cyclophosphamide. Working with a rat model of multiple drug exposures, the team combined two powerful approaches: they measured the activity of circadian rhythm genes in the ovary, and they ran proteomic analysis to survey the full complement of proteins whose abundance shifted after treatment. The results converged on a surprising culprit. The ovaries of drug-exposed animals showed abnormal expression of circadian rhythm genes, and proteomics revealed a dramatic drop in one protein in particular: riboflavin kinase, abbreviated RFK, the enzyme that initiates the cellular processing of vitamin B2.

That finding might sound obscure, but riboflavin kinase sits at the head of a metabolic pathway with far-reaching consequences. The enzyme converts riboflavin, the vitamin better known as B2, into flavin mononucleotide, which is then elaborated into flavin adenine dinucleotide, or FAD, one of the most indispensable cofactors in biology. FAD participates in hundreds of redox reactions, shuttling electrons through the metabolic machinery that keeps cells alive. The new study adds a second, less appreciated role to that list: FAD is also a structural partner for the circadian clock, because it competes with the clock proteins cryptochrome 1 and 2 for binding to the ubiquitin E3 ligase, the cellular machine that tags proteins for destruction.

Here is where the chemistry becomes elegant. Cryptochromes are the workhorse repressors of the mammalian circadian oscillator, the proteins that help cells keep a roughly 24-hour rhythm of gene activity. Like all proteins, they are constantly being built and broken down, and the ubiquitin E3 ligase is responsible for their degradation. FAD competes with the cryptochrome proteins for access to that ligase, which means that when FAD levels are adequate, the degradation machinery is partially occupied and the cryptochromes survive longer, stabilizing the clock. When FAD runs short, the ligase turns its full attention to cryptochrome 1 and 2, and the clock proteins are chewed up faster than the cell can replace them.

The rat experiments showed precisely this sequence unfolding after cyclophosphamide exposure. Riboflavin kinase expression fell, riboflavin metabolism faltered, FAD synthesis was inhibited, and the cryptochrome proteins were degraded at an accelerated rate. The circadian rhythm regulation of the ovary, a tissue whose follicular development, hormone secretion and ovulation are all coordinated by daily molecular rhythms, fell into disarray. In other words, the chemotherapy drug was not only attacking the DNA of dividing granulosa cells; it was quietly dismantling the metabolic and temporal infrastructure those cells depend on to function.

To test whether the connection was causal rather than coincidental, the researchers turned to molecular experiments in which they knocked down riboflavin kinase directly. The results reinforced the model. Suppressing the enzyme lowered levels of FAD synthase, the downstream enzyme that completes FAD production, and it worsened the degradation of cryptochrome 1 and 2. Circadian rhythm regulation was disrupted, and the consequences rippled into the function of ovarian granulosa cells, the somatic cells that nurse developing follicles and produce the hormones essential for fertility. With their clock destabilized and their metabolism compromised, the granulosa cells declined, and ovarian aging accelerated.

The most clinically tantalizing result came from the rescue experiment. When the researchers supplemented the system with FAD, the cascade of damage was mitigated. Restoring the flavin cofactor eased the pressure on the cryptochrome proteins, helped re-establish circadian regulation and protected granulosa cell function. In the framework of the study, FAD supplementation acted as a counterweight to the riboflavin metabolism defect that cyclophosphamide had created, suggesting a potential strategy for shielding the ovary during chemo. The authors conclude that cyclophosphamide can impair ovarian function by causing dysregulation of riboflavin metabolism, which in turn drives abnormal circadian rhythms.

The implications extend beyond oncology. Premature ovarian insufficiency affects roughly one percent of women and carries consequences that reach far beyond fertility, including bone loss, cardiovascular risk and psychological distress. If a substantial share of chemotherapy-induced ovarian damage is mediated through a metabolic cofactor rather than through DNA strand breaks alone, then the protective options broaden considerably. Dietary and pharmacological interventions aimed at preserving riboflavin metabolism, or at stabilizing cryptochrome proteins directly, could in principle complement the existing approaches to fertility preservation, which currently rely on egg or embryo freezing and on temporary ovarian suppression with hormonal analogs during treatment.

The study also adds the ovary to a growing list of tissues whose health appears to depend on the integrity of their peripheral circadian clocks. Circadian biologists have shown that nearly every organ runs its own internal timing system, synchronized by the brain’s master clock but capable of autonomous oscillation, and that disrupting these local clocks impairs tissue function. The ovary is an especially rhythm-sensitive organ: follicle maturation, steroidogenesis and ovulation follow daily patterns, and granulosa cells express clock genes whose cycling is thought to coordinate these processes. A chemotherapeutic agent that destabilizes cryptochrome proteins in granulosa cells is therefore attacking the ovary at a level that standard genotoxicity models never captured.

As with any animal study, the road from rat ovaries to human clinics is long, and the findings, published open access with support from the National Natural Science Foundation of China, will need validation in human ovarian tissue and eventually in patients. The dosing, timing and safety of FAD supplementation alongside chemotherapy remain to be established, and it is far too early for patients undergoing cyclophosphamide treatment to draw practical conclusions. But the study reframes a familiar hazard in a new light. A drug long understood as a DNA-damaging agent now appears to sabotage the ovary through a second route, by starving it of a vitamin-derived cofactor that keeps its cellular clocks running, and that second route, unlike DNA damage itself, may be one medicine can actually repair.

Subject of Research: Mechanisms of cyclophosphamide-induced ovarian damage via riboflavin metabolism and circadian rhythm disruption

Article Title: Cyclophosphamide as a reproductive hazard: disrupted riboflavin metabolism and circadian rhythms drive ovarian decline

Article References: Peng, Y., Ma, Z., Hu, D., Wu, S., Shi, J., Chen, J., & Tan, Y. (2026). Cyclophosphamide as a reproductive hazard: disrupted riboflavin metabolism and circadian rhythms drive ovarian decline. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02293-6

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02293-6

Keywords: cyclophosphamide, ovarian aging, premature ovarian insufficiency, riboflavin kinase, FAD, cryptochrome, circadian rhythm, granulosa cells, chemotherapy, fertility, vitamin B2, ovary

The clinical stakes are considerable. Ovarian dysfunction affects hundreds of millions of women worldwide, yet treatment remains largely symptomatic because the underlying causes of most of these conditions remain poorly understood. PCOS, characterized by irregular ovulation, elevated androgen levels, and polycystic ovarian morphology, is a leading cause of infertility and metabolic disease. POI, in which ovarian function ceases before the age of forty, robs women of fertility and exposes them to long-term risks such as osteoporosis and cardiovascular disease. Ovarian aging, meanwhile, sets the biological clock that constrains reproductive windows. Because etiology-based treatments are scarce, the review’s central proposition—that manipulating the gut microbiome could influence ovarian physiology—has generated significant interest among clinicians and researchers alike.

The authors organize the mechanisms of gut-ovary communication into three principal channels: microbial metabolite signaling, immune regulation, and hormonal crosstalk. The first channel centers on the extraordinary chemical factory that the gut microbiome represents. Gut bacteria ferment dietary fibers and other substrates into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These molecules do more than nourish the cells lining the colon; they enter systemic circulation, modulate gene expression, influence insulin sensitivity, and can affect granulosa cells and other ovarian cell types that govern follicle development. Disruptions in SCFA-producing bacterial populations, the review notes, have been repeatedly observed in women with PCOS and other ovarian pathologies, raising the possibility that metabolite deficits contribute directly to disease mechanisms rather than merely accompanying them.

The second channel, immune regulation, reflects the intimate relationship between the gut microbiota and the host immune system. Roughly seventy percent of the body’s immune cells reside in gut-associated lymphoid tissue, where microbial signals calibrate the balance between inflammatory and anti-inflammatory responses. A disturbed microbial community—a state known as dysbiosis—can weaken the intestinal barrier, allowing bacterial components such as lipopolysaccharide to leak into circulation and trigger low-grade systemic inflammation. Chronic inflammation is a well-documented feature of PCOS and is implicated in the progressive follicle depletion seen in ovarian aging. By shaping inflammatory tone, the review argues, gut microbes may either protect the ovary’s finite pool of follicles or accelerate its functional decline.

The third channel, hormonal crosstalk, is perhaps the most conceptually striking. Gut bacteria participate directly in the metabolism of estrogens through enzymes collectively described as the estrobolome, which deconjugate estrogen metabolites and influence how much active hormone re-enters circulation. Microbes also modulate the enteroinsular axis, affecting insulin secretion, and insulin resistance is a central driver of the hyperandrogenism that defines PCOS. Conversely, ovarian hormones themselves reshape the gut environment: estrogen influences gut permeability and microbial composition, creating a genuine feedback loop rather than a one-way street. This bidirectionality means that ovarian pathology can perturb the microbiome just as dysbiosis can perturb the ovary, complicating efforts to disentangle cause from effect.

Across the three conditions examined, the review documents consistent patterns of microbial alteration. Women with PCOS frequently show reduced microbial diversity and shifts in the relative abundance of specific bacterial taxa, changes that correlate with androgen levels, insulin resistance, and inflammatory markers. In POI, dysbiosis appears to coincide with diminished ovarian reserve and altered sex hormone profiles. In natural ovarian aging, compositional changes in the gut microbiome parallel the hormonal shifts of menopause, and some animal studies suggest that transferring gut microbes from young to old rodents—or vice versa—can influence ovarian function and fertility outcomes. Fecal microbiota transplantation (FMT) experiments in mouse models of PCOS have shown that gut microbes alone can transmit features of the disease, among the strongest available hints that the association is not merely correlative.

These findings open the door to microbiota-targeted interventions, which the authors evaluate with cautious optimism. Probiotics—live microorganisms administered to confer a health benefit—have been tested in small clinical trials, with some studies reporting improvements in hormonal parameters, metabolic markers, and menstrual regularity in women with PCOS, though results are heterogeneous and sample sizes remain modest. Dietary strategies, particularly those increasing fiber intake to boost SCFA production, represent a low-risk avenue for modulating the gut environment. FMT, while powerful in experimental settings, remains an investigational approach for ovarian conditions, carrying unresolved questions about safety, standardization, and long-term effects. The review emphasizes that none of these interventions has yet achieved the evidentiary threshold required for routine clinical recommendation.

Indeed, the authors devote considerable attention to the gaps that separate intriguing associations from actionable medicine. Most human studies to date are cross-sectional, capturing microbial snapshots at a single time point and thus unable to establish whether dysbiosis precedes or follows ovarian dysfunction. Animal models, while mechanistically informative, do not always translate faithfully to human physiology. Strain-level differences among bacteria, which may be decisive for function, are often invisible to the sequencing resolutions used in many studies. The review calls for longitudinal cohorts, randomized controlled trials, and mechanistic work that traces specific microbial metabolites to specific ovarian cell responses—steps it identifies as essential for causal validation and genuine clinical translation.

The concept of the gut-ovary axis also fits within a broader rethinking of reproductive endocrinology. The gut-brain axis has already reshaped how neuroscientists view mood and cognition, and the gut-liver and gut-immune axes have similarly redrawn their fields. Extending this framework to the ovary suggests that reproductive health may be influenced by factors far beyond the reproductive tract: diet, antibiotics, environmental exposures, and the microbial inheritance received at birth all leave fingerprints on the gut ecosystem, and potentially, by extension, on the ovary. For patients, this reframing carries a hopeful message—that conditions long treated as fixed or purely genetic might one day be modulated through the microbial world within.

For now, the review functions as both a synthesis and a roadmap. It consolidates evidence that gut dysbiosis accompanies PCOS, POI, and ovarian aging; it delineates the metabolite, immune, and hormonal pathways through which microbes could plausibly act on the ovary; and it charts the research needed to convert correlation into causation and mechanism into therapy. The work, supported by the Key Research and Development Special Projects in Henan Province, arrives as reproductive medicine confronts rising rates of infertility and metabolic reproductive disease worldwide. Whether the gut-ovary axis ultimately yields new treatments or remains a compelling hypothesis, it has already succeeded in expanding the anatomical boundaries of reproductive science—drawing the ovary into conversation with an unexpected partner, the microbial universe of the gut.

Subject of Research: The role of the gut microbiome in ovarian function and reproductive disorders

Article Title: The gut-ovary axis: how microbial players orchestrate female reproductive health

Article References: Huang, Z., Cui, C., Chen, H., & Zhang, C. (2026). The gut-ovary axis: how microbial players orchestrate female reproductive health. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02194-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02194-8

Keywords: gut-ovary axis, gut microbiome, ovary, polycystic ovary syndrome, premature ovarian insufficiency, ovarian aging, fecal microbiota transplantation, short-chain fatty acids, probiotics, dysbiosis, reproductive health, microbiota

The research team, led by Nesrin Yilmaz of Erzincan Binali Yıldırım University in Turkey together with colleagues across several Turkish institutions, set out to answer a question that had never been directly addressed. Previous studies had shown that lamotrigine can alter intracellular ATP levels in a dose-dependent manner, and that this energetic disturbance promotes the generation of reactive oxygen species, the unstable molecules that chew through lipids, proteins, and DNA. What remained unknown was whether the ovary, an organ exquisitely sensitive to oxidative stress because of its finite pool of follicles, suffers the same fate, and whether supplementing ATP from outside the cell could counteract the damage.

To find out, the investigators divided forty-two female Wistar albino rats into seven groups of six animals each. One group served as a healthy control. A second received a low oral dose of lamotrigine, ten milligrams per kilogram of body weight, roughly comparable to standard therapeutic exposure. A third received a high oral dose of thirty milligrams per kilogram. The remaining four groups received either ATP at five milligrams per kilogram intraperitoneally or melatonin at ten milligrams per kilogram orally, each paired with either the low or the high lamotrigine dose. Crucially, both protective agents were administered one hour before lamotrigine every day for thirty days, a pre-treatment design intended to ensure that the antioxidants were already on board when the drug hit the tissue.

At the end of the thirty-day period, the researchers assembled an unusually comprehensive picture of ovarian health. They quantified oxidant and antioxidant biomarkers in ovarian tissue, measured serum levels of anti-Mullerian hormone, or AMH, a widely used clinical marker of the ovarian follicle reserve, graded histopathological injury under the microscope, and deployed a double-immunofluorescence technique to visualize, cell by cell, the accumulation of 8-hydroxy-2′-deoxyguanosine, a signature of oxidative DNA damage, along with dityrosine, a marker of protein oxidation, and the inflammatory enzymes cyclooxygenase-1 and cyclooxygenase-2.

The results drew a sharp line between the two doses. Low-dose lamotrigine produced no detectable oxidative, histopathological, or immunofluorescence alterations at all, a reassuring finding for patients on standard regimens, at least in this animal model. High-dose lamotrigine, by contrast, told a very different story. Oxidant markers climbed significantly, antioxidant defenses fell, and serum AMH dropped, all accompanied by severe follicular degeneration visible in the tissue sections. The immunofluorescence work added molecular texture to the damage: pronounced immunopositivity for 8-OHdG and dityrosine signaled that both DNA and proteins had taken an oxidative beating, while cyclooxygenase-2, the inducible inflammatory enzyme, lit up strongly even as cyclooxygenase-1, its constitutive counterpart, was suppressed.

That COX-1/COX-2 imbalance is more than a technical footnote. Cyclooxygenase enzymes convert arachidonic acid into prostaglandins that participate in ovulation, luteal function, and inflammatory signaling within the ovary. A simultaneous rise in the inducible COX-2 and fall in the constitutive COX-1 suggests a shift from homeostatic prostaglandin production toward an inflammatory program, the kind of shift that can disrupt follicular development and impair the delicate hormonal crosstalk between the ovary and the rest of the reproductive axis. Combined with the decline in AMH, which reflects a shrinking or damaged follicle pool, the picture is one of genuine reproductive vulnerability, not merely incidental biochemical noise.

The most striking result, however, concerned the two protective strategies. When ATP was given before high-dose lamotrigine, it attenuated the oxidant surge, restored antioxidant levels, preserved AMH, reduced histopathological injury, and dampened the abnormal 8-OHdG, dityrosine, and COX-2 immunopositivity more effectively than melatonin did. This is a noteworthy result precisely because melatonin is something of a benchmark in oxidative-stress research, a hormone with a long track record of protecting reproductive tissues in animal models. For ATP to outperform it suggests that the mechanism of lamotrigine-induced injury is not simply an excess of free radicals but something more fundamental: a collapse of cellular energy homeostasis that melatonin, however capable a radical scavenger, cannot fully correct.

The authors propose that exogenous ATP works by restoring cellular energy balance and modulating inflammatory signaling, thereby addressing the injury at its energetic root rather than mopping up radicals downstream. The idea has an elegant logic. If lamotrigine perturbs intracellular ATP levels and that perturbation drives reactive oxygen species generation, then replenishing ATP supplies the cell with the resources it needs to run its own antioxidant machinery, including the energy-dependent repair enzymes that excise oxidized DNA bases and refold or degrade damaged proteins. In this framing, melatonin treats the symptom while ATP treats the cause, which would explain the superior outcomes across the biochemical, histological, and immunofluorescence readouts.

Several caveats deserve emphasis before anyone extrapolates these findings to the clinic. The study was conducted in rats over thirty days, with doses and routes of administration that do not map one-to-one onto human pharmacology. The high lamotrigine dose of thirty milligrams per kilogram exceeds typical human therapeutic exposure on a body-weight basis, and the ATP was delivered intraperitoneally, raising questions about how exogenous ATP would reach ovarian tissue in patients. The pre-treatment design, in which protection was given an hour before the drug, also differs from the real-world scenario in which a patient is already taking lamotrigine before any protective agent is considered. Whether ATP remains protective when given alongside or after the drug is unknown.

Even so, the study opens a genuinely novel therapeutic direction. If the findings hold up in translational work, cellular bioenergetic restoration could become an adjunctive strategy for protecting the ovary during chronic high-dose lamotrigine exposure, and perhaps during other drug treatments known to disturb cellular energy metabolism. For the many young women who must take antiseizure medications for years, the prospect of a fertility-sparing intervention is compelling. The Turkish team’s demonstration that a molecule as fundamental as ATP can shield the ovary more effectively than a celebrated antioxidant reframes drug-induced reproductive injury as, at least in part, an energy problem, and energy problems may have energy solutions. Further studies in larger animal models and, eventually, carefully designed clinical trials will determine whether this laboratory insight can be translated into a practical therapy for patients.

Subject of Research: The protective effects of exogenous adenosine triphosphate against lamotrigine-induced oxidative ovarian injury in rats

Article Title: ATP mitigates high-dose lamotrigine-induced oxidative ovarian injury in rats more effectively than melatonin: insights from biochemical parameters, histopathology, and 8-OHdG, dityrosine, and COX-1/COX-2 double immunofluorescence

Article References: Yilmaz, N., Paltaci, S. I., Yavuzer, B., Sarigul, C., Ozkaraca, M., Gungor, A., Suleyman, B., Mammadov, R., & Suleyman, H. (2026). ATP mitigates high-dose lamotrigine-induced oxidative ovarian injury in rats more effectively than melatonin: insights from biochemical parameters, histopathology, and 8-OHdG, dityrosine, and COX-1/COX-2 double immunofluorescence. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02273-w

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02273-w

Keywords: lamotrigine, adenosine triphosphate, melatonin, oxidative stress, ovary, ovarian injury, anti-Mullerian hormone, 8-OHdG, dityrosine, cyclooxygenase, rats, reproductive toxicology